Download PDF
Thromb Haemost 1997; 78(04): 1167-1172
DOI: 10.1055/s-0038-1657709
Review Article
Schattauer GmbH Stuttgart

Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients

Maaike Kockx
1   The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Moniek P M de Maat
1   The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Haye C Knipscheer
2   The Department of Vascular Medicine, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands
,
John J P Kastelein
2   The Department of Vascular Medicine, Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands
,
Cornelis Kluft
1   The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Hans M G Princen
1   The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Teake Kooistra
1   The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 31 1996

Accepted after resubmission 05 June 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Evaluation of fibrate treatment in humans has focused primarily on its anti-lipidaemic effects. A potentially favourable haemostasis-modulating activity of fibrates has also been recognized but the data are not consistent. We sought to learn more about this variability by examining the effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in primary hyperlipidaemic patients after six and twelve weeks of treatment using different assay systems for PAI-1 and fibrinogen. Although both fibrates effectively lowered triglyceride and cholesterol levels, no effect on the elevated baseline antigen levels of t-PA and PAI-1 was observed after fibrate treatment. However, both fibrates influenced plasma fibrinogen levels, albeit in a different way. Fibrinogen antigen levels were elevated by 17.6% (p <0.05) and 24.3% (p <0.001) with gemfibrozil after six and twelve weeks, respectively, whereas with ciprofibrate there was no effect. Using a Clauss functional assay with either a mechanical end point or a turbidity-based end point, no significant change in fibrinogen levels was seen after six weeks of gemfibrozil treatment. However, after twelve weeks, gemfibrozil enhanced functional fibrinogen levels by 7.2% (p <0.05) as assessed by the Clauss mechanical assay, but decreased functional fibrinogen levels by 12.5% (p <0.0001) when a Clauss assay based on turbidity was used. After six or twelve weeks of ciprofibrate treatment, functional fibrinogen levels were decreased by 10.1% (p <0.001) and 10.5% (p <0.0001), respectively on the basis of Clauss mechanical and by 14.2% (p <0.001) and 28.2% (p <0.0001), respectively with the Clauss turbidimetric assay. A remarkable and consistent finding with both fibrates was the decrease in functionality of fibrinogen as assessed by the ratio of functional fibrinogen (determined by either of the two Clauss assays) to fibrinogen antigen.

Taken together, our results indicate that at least part of the variability in the effects of fibrates on haemostatic parameters can be explained by intrinsic differences between various fibrates, by differences in treatment period and/or by the different outcomes of various assay systems. Interestingly, the two fibrates tested both reduced the functionality of fibrinogen.

 

  • References

  • 1 Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 332: 512-521
    CrossrefPubMedGoogle Scholar
  • 2 Sirtori CR, Chiesa G. Effects of lipid-lowering agents and other treatment regimens on serum lipoproteins. Curr Opin Lipidol 1990; 1: 262-269
    CrossrefPubMedGoogle Scholar
  • 3 Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994; 111: 161-174
    CrossrefPubMedGoogle Scholar
  • 4 Tikkanen MJ. Fibric acid derivatives. Curr Opin Lipidol 1992; 3: 29-33
    CrossrefPubMedGoogle Scholar
  • 5 Thompson SG, Kienast J, Pyke S, Haverkate F, Van deLoo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641
    CrossrefPubMedGoogle Scholar
  • 6 Meade TW. Haemostatic function and arterial disease. Br Med Bull 1994; 50: 755-775
    CrossrefPubMedGoogle Scholar
  • 7 Keber I, Lavre J, Sue S, Keber D. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates. Fibrinolysis 1994; 8: 57-59
    PubMedGoogle Scholar
  • 8 Branchi A, Rovelline A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Andersen P, Smith P, Seljeflot I, Brataker S, Amesen H. Effect of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174-177
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Haire WD. Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertrigly-ceridemic patients with a history of thrombosis. Thromb Res 1991; 64: 493-501
    CrossrefPubMedGoogle Scholar
  • 11 Brӧijersén A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. Arterioscler Thromb Vase Biol 1996; 16: 511-516
    CrossrefPubMedGoogle Scholar
  • 12 Avellone G, Di GarboV, Cordova R, Panno AV, Ranelli G, De SimoneR, Bompiani GD. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis 1993; 7: 416-421
    PubMedGoogle Scholar
  • 13 Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment FI+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503-506
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 O’Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC. A pilot study of the effect of gemfibrozil on some haemato-logical parameters. Thromb Res 1982; 26: 275-279
    CrossrefPubMedGoogle Scholar
  • 15 Meijer P, Pollet DE, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem 1994; 40: 110-115
    PubMedGoogle Scholar
  • 16 Kluft C, Jie AFH. Comparison of specificities of antigen assays for plasminogen activator inhibitor 1 (PAI-1). Fibrinolysis 1990; 4: 136-137
    PubMedGoogle Scholar
  • 17 Halbmayer WM, Haushofer A, Schӧn R, Radek J, Fischer M. Comparison of a new automated kinetically determined fibrinogen assay with the 3 most used fibrinogen assays (functional, derived and nephelometric) in Austrian laboratories in several clinical populations and healthy controls. Haemostasis 1995; 25: 114-123
    PubMedGoogle Scholar
  • 18 De MaatMPM, Kamerling SWA, Kluft C. The sensitivity of some clotting rate and immunological fibrinogen assays for high, low and low’ molecular weight forms of fibrinogen. In: Regulation and modulation of the plasma fibrinogen level. Thesis. University of Rotterdam ISBN ISBN: 90-5412-020-7 1995. pp 29-46
    Google Scholar
  • 19 Simpson IA, Lorimer R, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985; 54: 442-444
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1987; 71: 220-225
    PubMedGoogle Scholar
  • 21 Knipscheer HC, De ValoisJC, Van denEnde B, Ten CateJ, Kastelein JJP. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia. Atherosclerosis 1996; 124: 75-81
    CrossrefPubMedGoogle Scholar
  • 22 Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10 (Suppl. 02) 171-179
    PubMedGoogle Scholar
  • 23 Hoegee-de NobelE, Voskuilen M, Briët E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemost 1988; 60: 1-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Von ClaussA. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogenes. Acta Haematol 1957; 17: 141-153
    PubMedGoogle Scholar
  • 25 Huber K, Beckmann R, Lang I, Schuster E, Binder BR. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis 1989; 3: 41-43
    PubMedGoogle Scholar
  • 26 Nieuwenhuizen W, Laterveer R, Hoegee-de NobelE, Bos R. A one-step enzyme immunoassay for total plasminogen activator inhibitor-1 antigen in human plasma. Blood Coag Fibrinol 1995; 6: 268-272
    CrossrefPubMedGoogle Scholar
  • 27 Seifried E, Oethinger M, Tanswell P, Hoegee-de NobelE, Nieuwenhuizen W. Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogen. Thromb Haemost 1993; 69: 321-327
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Hoffmann JJML, Vijgen M, Nieuwenhuizen W. Comparison of the specificity of four fibrinogen assays during thrombolytic therapy. Fibrinolysis 1990; 4: 121-123
    PubMedGoogle Scholar
  • 29 De MaatMPM, Arnold AER, Van BurenS, Wilson JHP, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Res 1993; 70: 349-354
    CrossrefPubMedGoogle Scholar
  • 30 Regañon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release. Thromb Haemost 1993; 70: 978-983
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Holm B, Nilsen EWT, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 84: 509-516
    PubMedGoogle Scholar
  • 32 Meade TW, Brozovic M, Haines AP, Imenson JD, Mellows S, Miller GJ, North MRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-538
    PubMedGoogle Scholar
  • 33 ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 08-17
    PubMedGoogle Scholar
  • 34 Blombäck B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 01-75
    CrossrefPubMedGoogle Scholar
  • 35 Collet J, Mishal Z, Vasse M, Mirshahi M, Caen J, Soria C, Soria J. Pharmacological approaches of fibrin gel architecture modulation and thrombus degradation: its implication in atherogenesis and thromboembolism disease. Thromb Res 1994; 75: 353-359
    CrossrefPubMedGoogle Scholar
  • 36 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST, Mosesson MW, DiOrio JP, Siebenlist K, Legrand C, Soria J, Soria C, Caen JP. The molecular basis for fibrinogen Dusart (Aα 554 Arg → Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91: 1637-1642
    CrossrefPubMedGoogle Scholar
  • 37 Fatah K, Silveira A, Tomvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Brӧijersén A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 1996; 76: 171-176
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Hamsten A, Walldius G, Szamosi A, Blombäck M, De FaireU, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 4: 3-9
    PubMedGoogle Scholar
  • 40 Mussoni L, Mannucci L, Sirtori M, Camera M, Madema P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27
    CrossrefPubMedGoogle Scholar
  • 41 Scarabin P-Y, Plu-Bureau G, Zitoun D, Bara L, Guize L, Meyer SamamaM. Changes in haemostatic variables induced by oral contraceptives containing 50 μg or 30 μg oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 1995; 74: 928-932
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Oosthuizen W, Vorster HH, Jerling JC, Barnard HC, Smuts CM, Silvis N, Druger A, Venter CS. Both fish oil and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb Haemost 1994; 72: 557-562
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Barriocanal LA, Mishra V, Tarbit M, Kesteven P, Alberti KGMM, Walker M. The effect of triglyceride infusion on the regulators of fibrinolysis. Fibrinolysis 1995; 9: 243-246
    PubMedGoogle Scholar
  • 44 Heller FR, Parfonry A, Descamps O, Desager J, Harvengt C. Effects of gemfibrozil on plasma lipoproteins, plasma activities of hepatic enzymes, and hemostatic variables in hypertriglyceridemic patients. Curr Therap Res 1995; 56: 597-606
    CrossrefPubMedGoogle Scholar